The European Medicines Agency (EMEA) has issued a draft guideline explaining the new accelerated assessment procedure for products of major therapeutic interest that was introduced by Regulation (EC) No 726/20041,2.
Under the regulation, which came fully into effect on 20 November 2005, a company may ask for a product to...




